5-氯-6-(喹啉-3-氧基)吡啶-3-胺 | 1013695-64-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-氯-6-(喹啉-3-氧基)吡啶-3-胺
• 英文名称: 5-chloro-6-(quinolin-3-yloxy)pyridin-3-amine
• 英文别名: 5-chloro-6-(quinolin-3yloxy)-pyridin-3-yl amine；5-chloro-6-quinolin-3-yloxypyridin-3-amine
• CAS: 1013695-64-1
• 化学式: C₁₄H₁₀ClN₃O
• 分子量: 271.706
• InChiKey: HWYUMMAPPQQIDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氯-6-(喹啉-3-氧基)吡啶-3-胺 、 3,4-二氟苯-1-磺酰氯 生成 N-(5-氯-6-(喹啉-3-氧基)吡啶-3-基)-3,4-二氟苯磺酰胺
  参考文献：
  名称：

  3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS

  摘要：

  本发明提供了一种由通式(I)所代表的新化合物：它们的药学上可接受的盐和药学上可接受的溶剂，用于治疗与胰岛素抵抗或高血糖有关的代谢紊乱。本发明还涉及制备通式(I)化合物和含有它们的制药组合物的过程。

  公开号：

  US20090247574A1
• 作为产物：
  描述：

  2-羟基-5-硝基吡啶 在 喹啉 、 盐酸 、 sodium chlorate 、 水 、 caesium carbonate 、 tin(ll) chloride 、 三氯氧磷 作用下， 以 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 39.5h， 生成 5-氯-6-(喹啉-3-氧基)吡啶-3-胺
  参考文献：
  名称：

  WO2008/35306

  摘要：

  公开号：

文献信息

• METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS
  申请人：Marita Rosalind Adaikalasamy

  公开号：US20090318465A1

  公开（公告）日：2009-12-24

  The present invention relates to a method for identifying compounds that act as insulin-sensitizers. The method can include screening of test compounds in two assays of insulin sensitivity. This method can identify lead compounds for the treatment of disorders caused by insulin resistance to glucose uptake. This invention also includes methods for treating insulin resistance and related disorders.

  本发明涉及一种识别作为胰岛素敏感剂的化合物的方法。该方法可以包括在两种胰岛素敏感性测定中筛选试验化合物。该方法可以确定用于治疗由胰岛素抵抗引起的葡萄糖摄取紊乱的先导化合物。该发明还包括治疗胰岛素抵抗及相关疾病的方法。
• 3-amino-pyridine derivatives for the treatment of metabolic disorders
  申请人：Piramal Healthcare Limited

  公开号：US08269010B2

  公开（公告）日：2012-09-18

  The present invention provides novel compounds represented by the general formula (I): their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The invention also relates to a process for the manufacture of compounds of formula (I) and pharmaceutical compositions containing them.

  本发明提供了一种新的化合物，其通式表示为（I）：其药学上可接受的盐和药学上可接受的溶剂，可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。本发明还涉及制备通式（I）化合物的方法和包含它们的药物组合物。
• Method for identifying compounds that act as insulin-sensitizers
  申请人：Piramal Life Sciences Limited

  公开号：EP2256496A2

  公开（公告）日：2010-12-01

  The present invention relates to a method for identifying compounds that act as insulin-sensitizers. The method can include screening of test compounds in two assays of insulin sensitivity. This method can identify lead compounds for the treatment of disorders caused by insulin resistance to glucose uptake. This invention also includes methods for treating insulin resistance and related disorders. The present invention further relates to compounds for use in the treatment of disorders caused by insulin resistance to glucose uptake and disorders related thereto.

  本发明涉及一种鉴定可作为胰岛素敏感剂的化合物的方法。该方法可包括在两种胰岛素敏感性试验中筛选试验化合物。该方法可鉴定出用于治疗由胰岛素对葡萄糖摄取的抵抗所引起的疾病的先导化合物。本发明还包括治疗胰岛素抵抗及相关疾病的方法。 本发明进一步涉及用于治疗由胰岛素对葡萄糖摄取的抵抗引起的紊乱和相关紊乱的化合物。
• Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist
  作者：Swapnil Bajare、Jessy Anthony、Amrutha Nair、Rosalind Marita、Anagha Damre、Dharmeshkumar Patel、Chandrika Rao、H. Sivaramakrishnan、Nabajyoti Deka

  DOI：10.1016/j.ejmech.2012.10.027

  日期：2012.12

  The thiazolidinediones (TZDs) are a class of oral antidiabetic drugs that improve insulin sensitivity in patients with type 2 diabetes. Although the mechanism by which the TZDs lower insulin resistance is unclear, they are known to target the peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear hormone receptor. Ligands for PPAR gamma regulate adipocyte production and secretion of fatty acids as well as glucose metabolism, resulting in increased insulin sensitivity in adipose tissue, liver, and skeletal muscle. However, TZDs have several adverse effects, including weight gain and liver toxicity. Herein we report identification of non-TZD PPAR gamma agonists which exhibit beneficial effects similar to that of TZDs in animal models, but without the associated adverse effects. (C) 2012 Elsevier Masson SAS. All rights reserved.
• 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Piramal Life Sciences Limited

  公开号：EP2094687A1

  公开（公告）日：2009-09-02